WILEY

Learn more our COAs, visit **our website**

Accelerate your clinical studies with a rapid COA licensing process

Interview background

Wiley wanted to better understand how research teams select Clinical Outcome Assessments (COAs) for their clinical trials.

Conducting qualitative research* from March to April 2023 with both Wiley licensing partners/clients and pharmaceutical industry experts, we sought to identify how we could **accelerate** this process.

* 11 Interviewees were chosen by Wiley and were invited to share their experiences with an independent researcher.

The challenge: Efficiency of COA licensing

The pharmaceutical industry and licensing partners face licensing roadblocks to access COAs, including:

- Bottlenecks for identification of authors
- Legal back and forth
- Delays due to negotiations on terms and conditions (translations, migration, payment)
- Complexity of execution with a variable timeline of 4-6 weeks and up to +12 weeks

The solution: Streamline permissions with Wiley

Our licensing team have the knowledge and skills to cut processing time and execute COA licensing quickly to enhance the validity of clinical trials, demonstrate a treatment effect and secure a successful drug approval. Here's what clients said about their experience:

- "More responsive, transparent, faster timeline."
- "In terms of responsiveness and pricing and transparency, I would say [Wiley rates] very highly."
- "Responds quickly, good communication, valued relationship."
- "Responsive, straightforward answers."
- "Have a master license that works well, makes the process more efficient."

Our COA catalogue

COAs
90+

Society partners
40+

Key Therapies
8+

Translation with partner
Mapi Research Trust

Capabilities

280+
COAs Licensed in 2022

Permissions completed within 1-3 weeks
from initial query to full COA license execution

COAs processed in 3-4 days

* On average for Wiley-managed COAs